Clinical momentum Leverage Othera's Phase II trial for OT-551 targeting dry AMD and their positive interim results to position partnership or licensing discussions with ophthalmology manufacturers seeking novel AMD therapies.

Eye disease focus Target collaborations around age-related ocular diseases such as AMD, glaucoma, and neurodegenerative eye conditions, offering potential co-development or in-licensing opportunities for Othera's pipeline and expertise.

Mid-stage potential With a revenue range of 10-25M and a recent 24M in funding, present opportunities for strategic investors or partners to accelerate late-stage development, manufacturing scaling, or commercialization in select geographies.

Clinical-readiness leverage Offer contract development and manufacturing or regulatory support services to streamline OT-551’s progression, tapping into Othera’s Phase II data to de-risk clinical development for potential CRO/CDMO partners.

Smaller-company agility Position as a nimble partner for large pharma seeking boutique, innovative ophthalmology assets, highlighting low headcount, focused therapeutic area, and flexible collaboration terms to complement larger commercialization capabilities.